Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients.

abstract：:Beta-adrenoceptor antagonists are among the most commonly prescribed classes of drugs. They are indicated for the treatment of diseases such as hypertension and angina pectoris, in which long term therapy is often required. Since many beta-adrenoceptor antagonists have short plasma elimination half-lives, divided dail...

journal_title：Clinical pharmacokinetics

authors： Nace GS,Wood AJ

更新日期：1987-07-01 00:00:00

abstract：:Telithromycin is the first ketolide, which is a new class of antibacterial agents related to the macrolides that have structural modifications permitting dual binding to bacterial ribosomal RNA so that activity is retained against Streptococcus pneumoniae with macrolide-lincosamide-streptogramin(B) resistance. Clinica...

journal_title：Clinical pharmacokinetics

authors： Shi J,Montay G,Bhargava VO

更新日期：2005-01-01 00:00:00

abstract：:Serum concentration measurements of antibacterial agents are increasingly used to optimise drug dosage regimens. However, this approach is only justified for drugs with a low therapeutic index and poor predictability of serum concentrations, such as the aminoglycosides, chloramphenicol and vancomycin, whereas the peni...

journal_title：Clinical pharmacokinetics

authors： Wenk M,Vozeh S,Follath F

更新日期：1984-11-01 00:00:00

abstract：:The half-life of a drug, which expresses a change in concentration in units of time, is perhaps the most easily understood pharmacokinetic parameter and provides a succinct description of many concentration-time profiles. The calculation of a half-life implies a linear, first-order, time-invariant process. No drug per...

journal_title：Clinical pharmacokinetics

authors： Wright JG,Boddy AV

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase currently being developed for the management of hyperuricemia in patients with gout. OBJECTIVE:To investigate the pharmacokinetics, pharmacodynamics and safety of febuxostat over a range of oral doses in healthy subjects. METHODS:In a...

journal_title：Clinical pharmacokinetics

authors： Khosravan R,Grabowski BA,Wu JT,Joseph-Ridge N,Vernillet L

更新日期：2006-01-01 00:00:00

abstract：:The critically ill patient occupies an increasing amount of time and bed space in modern hospital practice, and also commands increasing expenditure. Drug therapy in these patients has, in the past, been based on data derived from healthy volunteers, fit anaesthetised patients undergoing minor operative procedures, or...

journal_title：Clinical pharmacokinetics

authors： Bodenham A,Shelly MP,Park GR

更新日期：1988-06-01 00:00:00

abstract：:Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only g...

journal_title：Clinical pharmacokinetics

authors： Rey E,Pons G,Olive G

更新日期：1992-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Buprenorphine has been shown to be effective in treating infants with neonatal opioid withdrawal syndrome. However, an evidence-based buprenorphine dosing strategy has not been established in the treatment of neonatal opioid withdrawal syndrome because of a lack of exposure-response data. The a...

journal_title：Clinical pharmacokinetics

authors： Mizuno T,McPhail BT,Kamatkar S,Wexelblatt S,Ward L,Christians U,Akinbi HT,Vinks AA

更新日期：2020-09-17 00:00:00

abstract：BACKGROUND AND OBJECTIVES:From a previously validated paediatric population pharmacokinetic model, it was derived that non-linear morphine maintenance doses of 5 μg/kg(1.5)/h, with a 50 % dose reduction in neonates with a postnatal age (PNA) <10 days, yield similar morphine and metabolite concentrations across patients...

journal_title：Clinical pharmacokinetics

authors： Krekels EH,Tibboel D,de Wildt SN,Ceelie I,Dahan A,van Dijk M,Danhof M,Knibbe CA

更新日期：2014-06-01 00:00:00

abstract：:Rapid drug delivery (arterial "boli') and high drug concentrations occur with nicotine inhaled in smoke. These are believed to be key elements in producing addiction to cigarettes. Preparations which reduce the rate of delivery and/or concentration of nicotine have been introduced as treatments for smoking cessation. ...

journal_title：Clinical pharmacokinetics

authors： Schneider NG,Lunell E,Olmstead RE,Fagerström KO

更新日期：1996-07-01 00:00:00

abstract：:Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabu...

journal_title：Clinical pharmacokinetics

authors： King JR,Zha J,Khatri A,Dutta S,Menon RM

更新日期：2017-10-01 00:00:00

abstract：:The pharmacokinetics of oral morphine sulphate as controlled release tablets ('MS-Contin') and solution were compared at steady-state. Plasma morphine concentrations were determined over 24 hours following the last dose of each drug when given in a randomised, crossover fashion to healthy subjects. Radioimmunoassay wa...

journal_title：Clinical pharmacokinetics

authors： Savarese JJ,Goldenheim PD,Thomas GB,Kaiko RF

更新日期：1986-11-01 00:00:00

abstract：:Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin...

journal_title：Clinical pharmacokinetics

authors： Scheen AJ

更新日期：2014-04-01 00:00:00

abstract：:Obesity is associated with physiological changes that can alter the pharmacokinetic parameters of many drugs. Vancomycin and the aminoglycosides are the only antibacterials that have been extensively investigated in the obese population. The apparent volume of distribution (Vd) and total body clearance of vancomycin a...

journal_title：Clinical pharmacokinetics

authors： Bearden DT,Rodvold KA

更新日期：2000-05-01 00:00:00

abstract：:The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, and difficult to predict as the mechanisms of these effects are not well understood. Since the majority of the published literature is concerned with cirrhotic liver disease, this review also focuses mainly on this area. Four di...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,McLean AJ

更新日期：1995-11-01 00:00:00

abstract：:The results of research studies conducted to date in vitro and in healthy volunteers are practically all concordant in demonstrating the lack of any kind of interference between famotidine and microsomal oxidative metabolism. The pharmacokinetics (elimination half-life, area under the plasma concentration-time curve, ...

journal_title：Clinical pharmacokinetics

authors： Dal Negro R,Pomari C,Turco P

更新日期：1993-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone ace...

journal_title：Clinical pharmacokinetics

authors： Xu XS,Ryan CJ,Stuyckens K,Smith MR,Saad F,Griffin TW,Park YC,Yu MK,De Porre P,Vermeulen A,Poggesi I,Nandy P

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:This study proposes a model-informed approach for therapeutic drug monitoring (TDM) of rifampicin to improve tuberculosis (TB) treatment. METHODS:Two datasets from pulmonary TB patients were used: a pharmacokinetic study (34 patients, 373 samples), and TDM data (96 patients, 391 samples) colle...

journal_title：Clinical pharmacokinetics

authors： van Beek SW,Ter Heine R,Keizer RJ,Magis-Escurra C,Aarnoutse RE,Svensson EM

更新日期：2019-06-01 00:00:00

abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

journal_title：Clinical pharmacokinetics

authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

更新日期：2018-07-01 00:00:00

abstract：:Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate ...

journal_title：Clinical pharmacokinetics

authors： Zandvliet AS,Schellens JH,Beijnen JH,Huitema AD

更新日期：2008-01-01 00:00:00

abstract：:Over the past few decades, the importance of applying pharmacokinetic principles to the design of drug regimens has been increasingly recognised by clinicians. From the perspective of antimicrobial chemotherapy, an improvement in clinical outcome and/or a reduction in toxicity are of primary interest. Before applicati...

journal_title：Clinical pharmacokinetics

authors： Li RC,Zhu M,Schentag JJ

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Febuxostat is a xanthine oxidase inhibitor indicated for gout and hyperuricemia. This work investigates potential clinically relevant covariates for febuxostat pharmacokinetics with a special focus on Asian race and bodyweight. METHODS:Febuxostat plasma concentrations from 141 male subjects we...

journal_title：Clinical pharmacokinetics

authors： Rekić D,Johansson S,Leander J

更新日期：2020-09-19 00:00:00

abstract：:The intracellular pharmacokinetics of the different classes of antimicrobials into surrogate markers of tissue accumulation (alveolar macrophages and/or total alveolar cells collected by means of bronchoalveolar lavage or peripheral white blood cells) was reviewed. The aim of this review was to discuss the clinical im...

journal_title：Clinical pharmacokinetics

authors： Pea F

更新日期：2018-02-01 00:00:00

abstract：:Data on the pharmacokinetics of ofloxacin in chronic renal failure, in patients who were not dialysed or were receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), are reviewed. In addition, a large pool of data obtained in patients with a wide range of renal dysfunction is provided. The good ab...

journal_title：Clinical pharmacokinetics

authors： Lameire N,Rosenkranz B,Malerczyk V,Lehr KH,Veys N,Ringoir S

更新日期：1991-11-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Losmapimod is an orally available, potent p38 mitogen-activated protein kinase inhibitor. It is in development as an anti-inflammatory drug in different therapeutic areas. Clinical studies have shown that losmapimod is well tolerated and safe in humans and several studies have shown its pharmac...

journal_title：Clinical pharmacokinetics

authors： Yang S,Lukey P,Beerahee M,Hoke F

更新日期：2013-03-01 00:00:00

abstract：:Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusi...

journal_title：Clinical pharmacokinetics

authors： Graham GG,Punt J,Arora M,Day RO,Doogue MP,Duong JK,Furlong TJ,Greenfield JR,Greenup LC,Kirkpatrick CM,Ray JE,Timmins P,Williams KM

更新日期：2011-02-01 00:00:00

abstract：:A reduction in plasma albumin concentration, as seen in patients with the nephrotic syndrome, is usually associated with a decrease in plasma protein binding of highly bound drugs. Therefore, the fraction of the unbound drug increases, but the absolute free concentration remains essentially unchanged due to a compensa...

journal_title：Clinical pharmacokinetics

authors： Gugler R,Azarnoff DL

更新日期：1976-01-01 00:00:00

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Dalcetrapib, a cholesteryl ester transfer protein (CETP) modulator, is a thioester pro-drug that is rapidly hydrolysed to generate a pharmacologically active thiol. The thiol covalently binds to plasma proteins as mixed disulfides, extensively distributes into plasma lipoprotein fractions, and ...

journal_title：Clinical pharmacokinetics

authors： Phelan M,Anzures-Cabrera J,Carlile DJ,Rowell L,Kuhlmann O,Arold G,Robson R,Bentley D

更新日期：2013-04-01 00:00:00

abstract：:Various pharmacokinetic models, both simple and complex, have been developed to describe the way in which the rate of hepatic elimination of drugs depends on hepatic blood flow, hepatic intrinsic clearance and unbound fraction of drug in blood. A model is necessary because it is not possible to measure the average blo...

journal_title：Clinical pharmacokinetics

authors： Morgan DJ,Smallwood RA

更新日期：1990-01-01 00:00:00